Collaboration Aims to Develop First Intranasal Therapy for Mild Traumatic Brain Injury Aka Concussion, Establishing a Comprehensive Test-to-Treat Platform SARASOTA, Fla. and RICHMOND, Va., Feb. 11, ...
(NYSE American: OGEN), a clinical-stage biotechnology company developing brain-targeted therapeutics through proprietary intranasal delivery technology, today announced that Alfred Hospital is now ...
BUFFALO, N.Y. — Active management after concussion is the best way for patients to recover and get back to school and work as quickly as possible, according to a Clinical Practice paper published ...
Oragenics submitted its Investigator's Brochure for ONP-002, preparing for a Phase II trial for mild traumatic brain injury. Oragenics, Inc., a biotechnology company based in Sarasota, Florida, ...
SARASOTA, Fla.--(BUSINESS WIRE)--Oragenics, Inc. (NYSE American: OGEN), a company focused on developing unique, intranasal pharmaceuticals for the treatment of neurological disorders, today announced ...
Clinical Trials Arena on MSN
Oragenics opens second site for ONP-002 phase IIa trial
Oragenics anticipates clinical data readout by year-end 2026 to support FDA application and US Phase IIb trials.
Almost half of people who suffer a concussion still show symptoms of brain injury six months later, reveals new research. Even mild concussions can cause long-lasting effects to the brain, say ...
The team at University Orthopedics offers accessible, effective, and important concussion treatments
Concussions are a Mild Traumatic Brain Injury (mTBI) that need to be taken seriously. As our overall understanding of concussions and recovery from these brain injuries improves, Physical Therapy has ...
If you or someone you love plays competitive sports, either with a few friends at the park or in the big leagues, concussions are probably high on your list of concerns. The Social Brain Blog, curated ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results